Autologous Tumor Infiltrating Lymphocytes GT201 clinical trials
Also written GT201.
How each study uses Autologous Tumor Infiltrating Lymphocytes GT201 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Tumor Infiltrating Lymphocytes GT201 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GT201
- 5
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Grit Biotechnology (5) · Gritbio Medicine, Inc. (1) · RenJi Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Autologous Tumor Infiltrating Lymphocytes GT201.
- Apr 2027Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsNot applicable · Grit Biotechnology
Studies
Open first, then newest update. How each study uses Autologous Tumor Infiltrating Lymphocytes GT201 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid TumorsRecruitingPhase 1/2Grit BiotechnologyNCT06144671Written as GT201
- Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.Not yet recruitingPhase 1/2Gritbio Medicine, Inc.NCT07766317Written as GT201
- Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsRecruitingNot applicableGrit BiotechnologyNCT06190275Written as GT201 in combination with PD-1 inhibitors
- Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic TumorsRecruitingEarly Phase 1RenJi HospitalNCT05724732Written as GT201
- Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid TumorsTerminatedPhase 1Grit BiotechnologyNCT05430360Written as GT201
- Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung CancerTerminatedNot applicableGrit BiotechnologyNCT06519669Written as GT201 injection
- Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid TumorsTerminatedPhase 1/2Grit BiotechnologyNCT05729399Written as GT201